This “Heads We Win, Tails We Still Win” Pharmaceutical Distributor Stock Is “Incredibly Cheap”

In regards to the stock of this high-quality pharmaceutical distributor, the author of today’s article declares that it “is not just cheap – it’s incredibly cheap.” But what about concerns the market currently has about this stock – namely Amazon’s entrance into the drug distribution space and White House rhetoric on drug prices? The author lays out how, under even the worst-case scenario for this company, it’s a “heads we win, tails we get less, but we still win” scenario for investors. For more, CLICK HERE.

3 Big Pharma Buy-And-Holds

When it comes to identifying stocks that you can buy and hold for years, the author of today’s article points to three important criteria: attractive valuations, great (and growing) dividends, and solid long-term growth prospects. He proceeds to highlight three big pharma stocks that appear to meet all three criteria – and which therefore could be solid long-term bets. For these three stocks – and some of the promising drug candidates in their pipelines – CLICK HERE.

Stocks To Cash In On The $35 Billion NASH Dash

Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for it. As such, this once obscure disease has become a top area of focus for drug makers, and as today’s article notes, “NASH is also predicted to be the next huge market opportunity for the biopharmaceutical industry, with some forecasting a global market size of as much as $35 billion per year.” For investors looking to cash in on the NASH dash, the author highlights a number of biopharmaceutical stocks to consider. For more, CLICK HERE.

The 21st Century Cures Act: How Investors Can Profit From This Potential “Boon For Big Pharma”

2017-01-07-19_16_06-morguefile-free-photographs-for-commercial-useToday’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans exorbitant amounts for the drugs they require. However, new legislation recently signed into law – the 21st Century Cures Act – seeks to streamline the approval process and bring new drugs to market faster, which the author notes “could be a boon for Big Pharma.” So, how can investors profit from this boon? The author highlights two top players in the generic pharmaceutical sector – as well as a biotech ETF that “gives you exposure to potentially huge moves from the little guys” – to consider. To read more, CLICK HERE.